BNTX revenueFY2025€2.87B
- FY YoY
- +4.3%
- 5Y CAGR
- +42.9%
BNTX revenue was €2.87B for fiscal 2025 (ended Dec 31, 2025), up 4.3% from fiscal 2024. Compound annual growth was +42.9% over 5 years. It rose in 4 of the last 8 fiscal years.
BioNTech SE (BNTX) financials
For fiscal 2025 (ended Dec 31, 2025), BioNTech SE reported €2.87B of revenue and -€1.14B of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €2.87B
- Revenue growth, YoY
- +4.3%
- Net income, FY2025
- -€1.14B
- Net margin
- -39.6%
- Free cash flow, FY2025
- €280.90M
- EPS, diluted, FY2025
- -€4.70
- Cash
- €7.68B
FY2017FY2025
FY2017FY2025
FY2017FY2025
BNTX revenue and earnings growth
BNTX net incomeFY2025-€1.14B
BNTX net income was -€1.14B for fiscal 2025 (ended Dec 31, 2025), compared with -€665.30M in fiscal 2024.
BNTX EPSFY2025-€4.70
BNTX diluted EPS was -€4.70 for fiscal 2025 (ended Dec 31, 2025), compared with -€2.77 in fiscal 2024.
BNTX free cash flowFY2025€280.90M
BNTX free cash flow was €280.90M for fiscal 2025 (ended Dec 31, 2025), compared with -€78.80M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | €2.87B | €2.75B | €3.82B | €17.31B | €18.98B | €482.30M | €108.60M | €127.58M | €61.60M |
| Cost of revenue | €641.80M | €541.30M | €599.80M | €3.00B | €2.91B | €59.30M | €17.40M | €13.69M | €9.32M |
| Gross profit | €2.23B | €2.21B | €3.22B | €14.32B | €16.07B | €423.00M | €91.23M | €113.89M | €52.28M |
| Research and development | €2.10B | €2.25B | €1.78B | €1.54B | €949.20M | €645.00M | €226.50M | €143.04M | €85.50M |
| Selling, general and admin | €514.40M | €531.10M | €495.00M | €481.70M | €276.80M | €94.00M | €45.50M | €26.33M | €23.52M |
| Operating income | -€1.40B | -€1.31B | €690.40M | €12.64B | €15.28B | -€82.40M | -€181.50M | -€53.85M | -€61.28M |
| Interest expense | €14.20M | €16.90M | €7.50M | €18.90M | €305.10M | €65.00M | €2.00M | €48.0K | €26.01M |
| Pre-tax income | -€1.05B | -€677.70M | €1.19B | €12.95B | €15.05B | -€145.80M | -€179.40M | -€47.66M | -€85.91M |
| Income tax | €85.30M | -€12.40M | €255.80M | €3.52B | €4.75B | -€161.00M | -€200.0K | €600.0K | €45.0K |
| Net income | -€1.14B | -€665.30M | €930.30M | €9.43B | €10.29B | €15.20M | -€179.10M | -€48.02M | -€85.65M |
| EPS, basic | -€4.70 | -€2.77 | €3.87 | €38.78 | €42.18 | €0.06 | -€0.85 | - | - |
| EPS, diluted | -€4.70 | -€2.77 | €3.83 | €37.77 | €39.63 | €0.06 | -€0.85 | - | - |
| Diluted shares | 241.7M | 240.4M | 242.7M | 249.8M | 259.7M | 248.5M | 211.5M | 190.7M | 166.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | €7.68B | €9.76B | €11.66B | €13.88B | €1.69B | €1.21B | €519.10M | €411.50M | €172.11M |
| Receivables | €924.20M | €1.46B | €2.16B | €7.15B | €12.38B | €165.50M | - | - | - |
| Inventory | €110.70M | €283.30M | €357.70M | €439.60M | €502.50M | €64.10M | €11.72M | €5.79M | - |
| Current assets | €16.15B | €18.80B | €19.53B | €21.92B | €15.07B | €1.67B | €560.15M | €448.96M | - |
| Goodwill | €367.90M | €380.60M | €362.50M | €61.20M | €57.80M | €53.70M | €2.98M | - | - |
| Total assets | €21.99B | €22.53B | €23.01B | €23.28B | €15.83B | €2.32B | €797.65M | €652.99M | - |
| Current liabilities | €2.14B | €2.52B | €2.07B | €2.95B | €3.48B | €606.00M | €138.14M | €126.12M | - |
| Long-term debt | - | - | - | - | €171.60M | €231.00M | €68.90M | - | - |
| Total debt | - | - | - | - | €171.60M | €231.00M | €68.90M | - | - |
| Total liabilities | €2.76B | €3.12B | €2.76B | €3.22B | €3.94B | €946.80M | €304.15M | €385.99M | - |
| Shareholders' equity | €19.22B | €19.41B | €20.25B | €20.06B | €11.89B | €1.37B | €493.50M | €267.00M | -€48.21M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | €456.00M | €207.70M | €5.37B | €13.58B | €889.70M | -€13.50M | -€198.50M | -€58.88M | -€52.56M |
| Capital expenditures | €175.10M | €286.50M | €249.40M | €329.20M | €127.50M | €66.00M | €38.60M | €29.90M | €24.32M |
| Free cash flow | €280.90M | -€78.80M | €5.12B | €13.25B | €762.20M | -€79.50M | -€237.10M | -€88.78M | -€76.88M |
| Investing cash flow | -€2.47B | -€2.08B | -€6.95B | -€35.30M | -€566.10M | -€144.80M | -€77.20M | -€66.45M | -€52.55M |
| Financing cash flow | -€52.90M | -€45.90M | -€778.60M | -€1.42B | €94.20M | €894.70M | €383.30M | €365.18M | -€1.64M |
| Dividends paid | - | €0 | €0 | €484.30M | €0 | €0 | - | - | - |
| Stock-based compensation | €106.20M | €100.90M | €51.40M | €108.60M | €93.90M | €32.10M | €30.20M | €7.64M | €5.91M |
| Depreciation and amortization | €382.80M | €298.00M | €183.40M | €123.30M | €75.20M | €38.70M | €33.90M | €21.98M | €10.53M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 4.3% | -28.0% | -77.9% | -8.8% | 3834.6% | 344.1% | -14.9% | 107.1% | - |
| Net income growth, YoY | - | - | -90.1% | -8.3% | 67613.8% | - | - | - | - |
| EPS growth, YoY | - | - | -89.9% | -4.7% | 65950.0% | - | - | - | - |
| Gross margin | 77.6% | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% | 84.0% | 89.3% | 84.9% |
| Operating margin | -49.0% | -47.8% | 18.1% | 73.0% | 80.5% | -17.1% | -167.1% | -42.2% | -99.5% |
| Net margin | -39.6% | -24.2% | 24.4% | 54.5% | 54.2% | 3.2% | -164.9% | -37.6% | -139.1% |
| Free cash flow margin | 9.8% | -2.9% | 134.1% | 76.5% | 4.0% | -16.5% | -218.3% | -69.6% | -124.8% |
| Return on equity | -5.9% | -3.4% | 4.6% | 47.0% | 86.5% | 1.1% | -36.3% | -18.0% | - |
| Return on assets | -5.2% | -3.0% | 4.0% | 40.5% | 65.0% | 0.7% | -22.5% | -7.4% | - |
| Current ratio | 7.54 | 7.45 | 9.43 | 7.43 | 4.33 | 2.75 | 4.05 | 3.56 | - |
| Debt to equity | - | - | - | - | 0.01 | 0.17 | 0.14 | - | - |
Source: XBRL data BioNTech SE files with the SEC, latest filing dated Mar 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BNTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $16.66B |
BNTX FAQ
9 questionsWhat is BNTX revenue?
BioNTech SE (BNTX) reported €2.87B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 4.3% from the year before.Is BNTX profitable?
No. BioNTech SE reported a net loss of €1.14B for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BNTX have?
BioNTech SE reported €7.68B in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is BNTX revenue growing?
BioNTech SE's revenue changed +4.3% in fiscal 2025, to €2.87B. Its compound annual growth rate was +42.9% over 5 years.What is BNTX gross margin?
BioNTech SE's gross profit was €2.23B on €2.87B of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 77.6%.What is BNTX free cash flow?
BioNTech SE generated €280.90M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of €456.00M less capital expenditures.What is BNTX earnings per share?
Diluted earnings per share were -€4.70 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did BNTX last report financial results?
The latest statements here come from BioNTech SE's 20-F filed on Mar 10, 2026, covering the period ended Dec 31, 2025.Where does this BNTX financial data come from?
Quantisnow builds these statements from the structured XBRL data BioNTech SE files with the SEC. It is provided for information only and is not investment advice.